Overview

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is an open, single-arm, prospective clinical study to evaluate the safety and efficacy of anti CD19 and CD22 CAR-T cell in the treatment of R/R B-ALL.
Phase:
Early Phase 1
Details
Lead Sponsor:
Hebei Senlang Biotechnology Inc., Ltd.
Collaborator:
Hebei Yanda Ludaopei Hospital
Treatments:
Cyclophosphamide
Fludarabine